Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 5/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | EGFR | P00533 | 13/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | KIF5B | P33176 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219862 | 1.00 | EPHA2 (0.70) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL7221058 | 1.00 | EPHA2 (0.70) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL7221051 | 1.00 | EPHA2 (0.70) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL4359307 | 0.90 | EPHA2 (0.85) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL6991150 | 0.88 | EPHA2 (0.69) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL7218842 | 0.88 | EPHA2 (0.69) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL1191334 | 0.87 | EGFR (0.70) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL7226666 | 0.87 | KDR (0.68) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL7221348 | 0.87 | EGFR (0.70) | EPHA2KDREGFREPHB4FBP1 | |
| SCHEMBL6998297 | 0.87 | EGFR (0.70) | EPHA2KDREGFREPHB4FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| EP-1315705-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2002018351-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EPHA2 1142/4885KDR 500/4885EGFR 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.